FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs